Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00

Tyra Biosciences (NASDAQ:TYRA) had its target price boosted by HC Wainwright from $30.00 to $32.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

TYRA has been the subject of a number of other reports. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Piper Sandler assumed coverage on Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Finally, Oppenheimer increased their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.40.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $15.97 on Monday. The stock has a market capitalization of $843.38 million, a P/E ratio of -9.45 and a beta of 1.01. The business has a 50 day simple moving average of $22.74 and a 200 day simple moving average of $19.92. Tyra Biosciences has a one year low of $10.60 and a one year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Equities analysts expect that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Activity

In other Tyra Biosciences news, CEO Todd Harris sold 10,092 shares of Tyra Biosciences stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96. Following the completion of the transaction, the chief executive officer now owns 1,479,528 shares in the company, valued at approximately $35,701,010.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 61,403 shares of company stock worth $1,582,774 over the last three months. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after acquiring an additional 8,324 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences during the third quarter valued at approximately $311,000. Bank of New York Mellon Corp lifted its holdings in Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after acquiring an additional 14,352 shares during the period. Finally, HighVista Strategies LLC purchased a new position in Tyra Biosciences in the second quarter worth $257,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.